We are live on ! Find out more
PYXS icon

Pyxis Oncology
PYXS

88 hedge funds and large institutions have $29.6M invested in Pyxis Oncology in 2025 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more call options, than puts

Call options by funds: $41K | Put options by funds: $36K

3.95% less ownership

Funds ownership: 53.06% → 49.11% (-3.9%)

11% less funds holding

Funds holding: 99 → 88 (-11)

19% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 26

40% less capital invested

Capital invested by funds: $49.2M → $29.6M (-$19.6M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

50% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 22

Holders
88
Holders Change
-11
Holders Change %
-11.11%
% of All Funds
1.18%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
11
Increased
21
Reduced
26
Closed
22
Calls
$41K
Puts
$36K
Net Calls
+$5K
Net Calls Change
-$1.5M

Top Buyers

1
TCM
Tang Capital Management
California
+$1.47M
2
P8IP
Pier 88 Investment Partners
California
+$390K
3
Renaissance Technologies
Renaissance Technologies
New York
+$385K
4
Morgan Stanley
Morgan Stanley
New York
+$272K
5
6CM
683 Capital Management
New York
+$180K

Top Sellers

1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$939K
2
Millennium Management
Millennium Management
New York
-$661K
3
HA
HHLR Advisors
Cayman Islands
-$597K
4
American Century Companies
American Century Companies
Missouri
-$365K
5
PA
Perceptive Advisors
New York
-$294K
Name Holding Trade Value Shares
Change 		Change in
Stake
P
1
Pfizer
New York
$6.89M – – –
LCM
2
Laurion Capital Management
New York
$3.55M – – –
BlackRock
3
BlackRock
New York
$3.21M -$96.3K -72,167 -2%
Millennium Management
4
Millennium Management
New York
$2.44M -$661K -495,630 -17%
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.39M -$5.9K -4,425 -0.2%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$1.09M +$35.6K +26,649 +2%
TCM
7
Tang Capital Management
California
$1.08M +$1.47M +1,100,000 New
PAI
8
Palo Alto Investors
California
$1.02M – – –
State Street
9
State Street
Massachusetts
$913K -$16K -11,970 -1%
Aberdeen Group
10
Aberdeen Group
United Kingdom
$895K – – –
IC
11
Ikarian Capital
Texas
$601K – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$570K +$385K +288,782 +98%
6CM
13
683 Capital Management
New York
$539K +$180K +135,000 +33%
Morgan Stanley
14
Morgan Stanley
New York
$438K +$272K +203,751 +84%
UBS Group
15
UBS Group
Switzerland
$389K -$66.5K -49,855 -11%
P8IP
16
Pier 88 Investment Partners
California
$383K +$390K +292,370 +297%
Northern Trust
17
Northern Trust
Illinois
$366K -$6.5K -4,870 -1%
DC
18
Decheng Capital
California
$320K – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$267K – – –
BFM
20
Boothbay Fund Management
New York
$177K – – –
Goldman Sachs
21
Goldman Sachs
New York
$158K -$31.9K -23,872 -13%
N
22
Nuveen
North Carolina
$125K – – –
SC
23
Schulhoff & Co
Ohio
$120K – – –
NW
24
NewEdge Wealth
Pennsylvania
$114K -$4 -3 -0%
Charles Schwab
25
Charles Schwab
California
$113K -$19.4K -14,524 -11%
1
2 3 4 5

PYXS Hedge Fund Activity: Q1 2025 in Review

88 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q1 2025, worth a combined $29.6M — down 40% from $49.2M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of PYXS and 11 opened new positions — a net loss of 11 holders — while 26 trimmed existing stakes and 21 added.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $1.47M. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $939K sold.

  • 88 institutional investors held Pyxis Oncology (PYXS) as of Q1 2025, down from 99 in Q4 2024.
  • Funds reported $29.6M of Pyxis Oncology stock for Q1 2025, down 40% quarter-over-quarter.
  • 11 funds opened new Pyxis Oncology positions in Q1 2025 and 22 closed out, a net change of -11 holders.
  • The largest Pyxis Oncology buyer in Q1 2025 was Tang Capital Management, an estimated $1.47M added.
  • The largest Pyxis Oncology seller in Q1 2025 was Jacobs Levy Equity Management, an estimated $939K sold.

Based on aggregated 13F filings for Q1 2025.